Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.19	$3.60	$1.24 ▼ $4.08	$845.81M	0.96	4.16 million shs	3.25 million shs
AVXL Anavex Life Sciences	$9.53 -0.2%	$10.48	$4.93 ▼ $14.44	$818.57M	0.8	1.02 million shs	750,369 shs
LYEL Lyell Immunopharma	$10.76 +1.0%	$10.28	$7.65 ▼ $32.40	$206.71M	-0.19	69,615 shs	21,762 shs
QURE uniQure	$15.70 +1.0%	$14.56	$4.45 ▼ $19.18	$861.41M	0.11	1.14 million shs	1.04 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	0.00%	-1.85%	-16.93%	+11.54%	+114.09%
AVXL Anavex Life Sciences	0.00%	-4.12%	-25.20%	+26.56%	+50.08%
LYEL Lyell Immunopharma	0.00%	+1.70%	+3.36%	+28.68%	-63.15%
QURE uniQure	0.00%	-2.97%	+3.22%	+3.56%	+123.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	3.9398 of 5 stars	3.5	2.0	4.0	2.7	0.8	0.6
AVXL Anavex Life Sciences	3.7719 of 5 stars	3.5	1.0	4.7	2.0	0.8	0.6
LYEL Lyell Immunopharma	3.7584 of 5 stars	2.8	5.0	0.0	3.0	4.2	1.3
QURE uniQure	2.4658 of 5 stars	3.5	1.0	0.0	2.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.00	Buy	$6.75	111.60% Upside
AVXL Anavex Life Sciences	3.00	Buy	$44.00	361.70% Upside
LYEL Lyell Immunopharma	1.50	Reduce	$15.00	39.41% Upside
QURE uniQure	3.00	Buy	$37.45	138.56% Upside

Current Analyst Ratings Breakdown

Latest LYEL, QURE, AKBA, and AVXL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
8/14/2025	QURE uniQure	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$30.00
8/13/2025	AKBA Akebia Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00
8/4/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00
7/30/2025	QURE uniQure	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$47.00
7/29/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $35.00
6/24/2025	LYEL Lyell Immunopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
5/30/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00
5/29/2025	QURE uniQure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$160.18M	5.28	N/A	N/A	$0.11 per share	29.00
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.06 per share	N/A
LYEL Lyell Immunopharma	$60K	3,444.99	N/A	N/A	$15.56 per share	0.69
QURE uniQure	$27.12M	31.76	N/A	N/A	($0.07) per share	-224.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$69.41M	-$0.17	N/A	N/A	N/A	-17.91%	N/A	-13.47%	11/6/2025 (Estimated)
AVXL Anavex Life Sciences	-$43M	-$0.57	N/A	N/A	N/A	N/A	-45.67%	-40.21%	N/A
LYEL Lyell Immunopharma	-$342.99M	-$24.29	N/A	N/A	N/A	-552,328.31%	-85.58%	-68.85%	11/6/2025 (Estimated)
QURE uniQure	-$239.56M	-$3.92	N/A	N/A	N/A	-1,387.98%	-1,010.74%	-33.27%	11/4/2025 (Estimated)

Latest LYEL, QURE, AKBA, and AVXL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q3 2025	AVXL Anavex Life Sciences	-$0.13	-$0.16	-$0.03	-$0.16	N/A	N/A
8/12/2025	Q2 2025	LYEL Lyell Immunopharma	-$3.80	-$2.89	+$0.91	-$2.89	$0.00 million	$0.01 million
7/29/2025	Q2 2025	QURE uniQure	-$0.89	-$0.69	+$0.20	-$0.69	$5.00 million	$5.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
LYEL Lyell Immunopharma	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.61	1.98	1.84
AVXL Anavex Life Sciences	N/A	8.93	8.93
LYEL Lyell Immunopharma	N/A	7.65	7.65
QURE uniQure	1.53	9.98	9.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
AVXL Anavex Life Sciences	31.55%
LYEL Lyell Immunopharma	66.05%
QURE uniQure	78.83%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
AVXL Anavex Life Sciences	11.40%
LYEL Lyell Immunopharma	22.30%
QURE uniQure	4.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	265.14 million	257.19 million	Optionable
AVXL Anavex Life Sciences	40	85.89 million	76.10 million	Optionable
LYEL Lyell Immunopharma	270	19.21 million	14.93 million	Optionable
QURE uniQure	500	54.87 million	52.24 million	Optionable

LYEL, QURE, AKBA, and AVXL Headlines

Recent News About These Companies

Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet

July 31, 2025 | zacks.com

uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript

July 29, 2025 | seekingalpha.com

uniQure Narrows Loss in Fiscal Q2

July 29, 2025 | fool.com

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

July 29, 2025 | zacks.com

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

July 29, 2025 | globenewswire.com

uniQure to Announce Second Quarter 2025 Financial Results

July 22, 2025 | globenewswire.com

uniQure: Price And Value Have Caught Up

June 17, 2025 | seekingalpha.com

uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

June 11, 2025 | globenewswire.com

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

June 2, 2025 | globenewswire.com

3 Top Genomics Stocks to Add to Your Portfolio in 2025

May 21, 2025 | zacks.com

Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?

May 14, 2025 | zacks.com

uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

May 9, 2025 | zacks.com

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

May 9, 2025 | globenewswire.com

uniQure to Announce First Quarter 2025 Financial Results

May 5, 2025 | globenewswire.com

uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?

April 21, 2025 | zacks.com

uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold

April 21, 2025 | seekingalpha.com

uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130

April 21, 2025 | seekingalpha.com

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

April 17, 2025 | globenewswire.com

UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates

February 27, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL, QURE, AKBA, and AVXL Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.19 0.00 (0.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.20 +0.02 (+0.47%)

As of 08/22/2025 07:44 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Anavex Life Sciences NASDAQ:AVXL

$9.53 -0.02 (-0.21%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$9.61 +0.08 (+0.84%)

As of 08/22/2025 07:07 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Lyell Immunopharma NASDAQ:LYEL

$10.76 +0.11 (+1.03%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$10.70 -0.06 (-0.60%)

As of 08/22/2025 04:10 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

uniQure NASDAQ:QURE

$15.70 +0.15 (+0.96%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$15.69 -0.01 (-0.06%)

As of 08/22/2025 07:19 PM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time